Suscribirse

Should segmentectomy indications be extended to NSCLC smaller than 3 cm without lymph node involvement? A retrospective single-center study - 09/07/25

Doi : 10.1016/j.resmer.2025.101179 
Damien Leveque a, , Soufiane Lebal b, Tristan Goudou a, Mihaela Giol a, Denis Debrosse a, Marielle LE Roux a, Thérésa Khalife-Hocquemiller a, Anna Vayssette a, Juliette Camuset a, Alexandra Rousseau b, Jalal Assouad a, Harry Etienne a
a Thoracic and Vascular Surgery Department, Tenon Hospital, East Paris Hospital Group, Sorbonne University, Paris, France 
b Clinical Research and Innovation Department (DRCI) of AP-HP, Clinical Research Unit of Eastern Paris (URCEST), Saint-Antoine Hospital, Paris, France 

Corresponding author.

Graphical abstract

The 5-year event-free survival (recurrence or death) between lobectomy and segmentectomy




Image, graphical abstract

El texto completo de este artículo está disponible en PDF.

Abstract

Introduction

Surgical resection remains the standard treatment for stage IA non-small cell lung cancers (NSCLC). The dual objective of this study is to compare long-term outcomes of lobectomies and segmentectomies for stage IA NSCLC and to identify prognostic factors for resected stage IA NSCLC.

Materials and Methods

This is a retrospective monocentric study including patients diagnosed with NSCLC smaller than 3 cm, without lymph node involvement, from November 2015 to November 2021. The primary endpoint was event-free survival (EFS), defined as time from surgery to recurrence or all-cause death. Secondary endpoints included overall survival, recurrence-free survival, and short-term postoperative outcomes (length of stay, drainage duration, 30-day mortality, and postoperative complications). Prognostic factors were analyzed using multivariate Cox regression adjusted for variables identified in univariate analysis.

Results

A total of 457 patients underwent surgery for stage cIA NSCLC during the 11study period. Of these, 176 (38.5 %) had a segmentectomy, and 281 (61.5 %) underwent lobectomy. Among patients with cT1N0 tumors, the 5-year event-free survival did not significantly differ between the segmentectomy and lobectomy groups (adjusted HR = 0.59 (0.32; 1.08), p = 0.086), with 5-year event-free rates of 75.0 % and 83.0 %, respectively (p = 0.054). Multivariate analysis revealed an association between nodule type (solid vs. ground-glass or mixed) and event-free survival (death and/or recurrence) ([adjusted HR =2.07 (1.17–3.66), p = 0.01)]. Vascular and/or lymphatic invasion is associated with a decrease in event-free survival (recurrence or death) [adjusted HR = 2.25 (1.29; 3.92), p = 0.004]. Conversion from segmentectomy to lobectomy occurred in 6 patients (3.4 %), and they were included in the lobectomy group for analysis.

Conclusion

For patients with clinical stage cIA NSCLC, segmentectomy appears to offer comparable oncologic outcomes to lobectomy. Tumor characteristics, including radiological appearance and histological factors, should be carefully considered when selecting the appropriate surgical strategy. Prospective multicenter studies are needed to confirm these findings.

El texto completo de este artículo está disponible en PDF.

Keywords : Segmentectomy, Lobectomy, Non-small cell lung cancer, Event-free survival, Recurrence


Esquema


© 2025  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 88

Artículo 101179- novembre 2025 Regresar al número
Artículo precedente Artículo precedente
  • Early mobilization and functional outcomes in cystic fibrosis patients after lung transplantation: A single-center retrospective study
  • Matthieu Reffienna, Jeremy Roussel, Gabor Kalman, Mathilde Labro, Charles Cerf, François Parquin
| Artículo siguiente Artículo siguiente
  • Does occupational exposure affect the surgical management of patients with non-small cell lung cancer? A single-center retrospective experience
  • Matthieu Thumerel, Camille Carles, Hugues Begueret, Quentin Thomas, Jacques Jougon, Carine Audoin, Jean-François Bernaudin, Patrick Brochard, Yaniss Belaroussi

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.